X-Message-Number: 7342
From: 
Date: Mon, 23 Dec 1996 20:46:26 -0500
Subject: Geron & CTSL

The current issue of the California Technology Stock Letter, by Michael
Murphy, has its feature article headlined DEATH VERSUS IMMORTALITY, and
recommends buying stock in Geron (GERN, Nasdaq) at a limit of $10, target of
$45 by 1999.

The article discusses the work of Geron (and other companies and
institutions) in studying the physiology of senescence, especially in
telomeres, and in bringing to market approaches to interfering with
senescence in normal cells and inducing senescence in malignant cells, at
various points in the physiological pathways. 

Murphy posits a time table for advances, including: Year 2000, various
"inside-the-cell therapies for senescence enter animal trials, including
antisense, ligands, ribozymes, cell signaling and gene therapy; Year 2006 for
FDA approval of an "inside-the-cell" therapy. 

If he is right, those who can hang on for another ten years may have it made,
or at least get another reprieve! ...and if any substantial number of people
begin to believe this, watch out!

CTSL address is P.O. Box 308, Half Moon Bay CA 94019, (415) 726-8495.

Robert Ettinger


Rate This Message: http://www.cryonet.org/cgi-bin/rate.cgi?msg=7342